Roundtable: Best Dividends in Health Care

Fool contributor Brian Orelli: Bristol-Myers Squibb (NYSE: BMY) will lose top-selling Plavix to generic competition in 2012, causing earnings to drop substantially. But in the long-term battle of pipeline versus patent cliff, it sure looks like the pipeline will come out the winner. The company expects 2013 earnings to drop to as little as $1.95 per share, a level just below what it managed last year. But that guidance was from before a couple of stellar wins: approval of melanoma drug Yervoy and positive clinical trial results for cardiovascular drug Eliquis, which it'll market with Pfizer (NYSE: PFE) . Behind those, the pipeline looks pretty solid, and Bristol-Myers has $6.8 billion that it can use to in-license drugs to help replace the missing Plavix revenue.... Read more